OrbusNeich Medical Group Holdings (FRA:Q8T) LT-Debt-to-Total-Asset : 0.01 (As of Jun. 2024)

View and export this data going back to 2023. Start your Free Trial

What is OrbusNeich Medical Group Holdings LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. OrbusNeich Medical Group Holdings's long-term debt to total assests ratio for the quarter that ended in Jun. 2024 was 0.01.

OrbusNeich Medical Group Holdings's long-term debt to total assets ratio increased from Jun. 2023 (0.01) to Jun. 2024 (0.01). It may suggest that OrbusNeich Medical Group Holdings is progressively becoming more dependent on debt to grow their business.

OrbusNeich Medical Group Holdings LT-Debt-to-Total-Asset Historical Data

The historical data trend for OrbusNeich Medical Group Holdings's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OrbusNeich Medical Group Holdings LT-Debt-to-Total-Asset Chart

OrbusNeich Medical Group Holdings Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.10

0.25

0.01

OrbusNeich Medical Group Holdings Semi-Annual Data
	Dec19	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial					0.01	0.01	-	0.01	0.01

OrbusNeich Medical Group Holdings LT-Debt-to-Total-Asset Calculation

OrbusNeich Medical Group Holdings's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	1.243	/	376.102
	=	0.00

OrbusNeich Medical Group Holdings's Long-Term Debt to Total Asset Ratio for the quarter that ended in Jun. 2024 is calculated as

LT Debt to Total Assets (Q: Jun. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Jun. 2024 )	/	Total Assets (Q: Jun. 2024 )
	=	2.194	/	385.939
	=	0.01

OrbusNeich Medical Group Holdings (FRA:Q8T) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

OrbusNeich Medical Group Holdings LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of OrbusNeich Medical Group Holdings's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

OrbusNeich Medical Group Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » OrbusNeich Medical Group Holdings Ltd (FRA:Q8T) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

06929:Hong Kong

Address

3rd Floor, Building 20E, Units 303 and 305, Hong Kong Science Park, Shatin New Town, Hong Kong, HKG

Website

https://www.orbusneich.com

OrbusNeich Medical Group Holdings Ltd is a China-based medical device maker of endovascular interventional instruments with majority reach. It launched its first research base in 2001 and was listed on the Hong Kong Exchange in 2022. As of 2023, OrbusNeich's majority revenue segment by geography is Japan with 24.7% of total revenue followed by Europe, the Middle East, and Africa, with 23.6% of total revenue. The Asia-Pacific region and the United States make up the balance. Its product segment is coronary interventional medical devices, such as scoring balloons, non-compliant balloons, or stents, together representing 82.7% of its total revenue.

OrbusNeich Medical Group Holdings Headlines

No Headlines